Dofetilide effect on human atrial action potential under normal and atrial fibrillation conditions. In silico study

Vista sencilla de ítem
dc.contributor.affiliationMATBIOM, Universidad de Medellín, Medellín, Colombiaspa
dc.contributor.affiliationPérez, S., Grupo de Dinámica Cardiovascular, Universidad Pontificia Bolivariana, Medellín, Colombiaspa
dc.contributor.affiliationCI2B, Universitat Politècnica de València, Valencia, Spainspa
dc.contributor.affiliationSaiz, J., CI2B, Universitat Politècnica de València, Valencia, Spainspa
dc.contributor.authorTobón C.
dc.contributor.authorPérez S.
dc.contributor.authorUgarte J.P.
dc.contributor.authorSaiz J.
dc.date.accessioned2017-12-19T19:36:43Z
dc.date.available2017-12-19T19:36:43Z
dc.date.issued2017
dc.description.abstractAtrial fibrillation is the most common sustained cardiac arrhythmia. Dofetilide is an antiarrhythmic drug for the treatment of chronic AF that specifically blocks the rapid component of the delayed rectifier potassium current IKr. Dofetilide prolongs the action potential duration and QT interval in a concentration-dependent fashion, therefore, the risk of QT prolongation is dose related. It is important to study the electrophysiological effects of dofetilide at different concentrations in human atrial cells. For this, we simulated the effects of dofetilide on human atrial cell and studied its effect on atrial action potential under normal conditions and during cAF. We developed a model of dofetilide effects on IKrand IKACh. Our results show that dofetilide blocks both currents in a fraction greater as the concentration increases, which results in an action potential duration lengthening. To our knowledge, this is the first work that has developed mathematical models of dofetilide effects on IKrand IKAChcurrents to study its effect on human atrial action potential. © Springer Nature Singapore Pte Ltd. 2017.eng
dc.identifier.doi10.1007/978-981-10-4086-3_10
dc.identifier.instnameinstname:Universidad de Medellínspa
dc.identifier.isbn9789811040856
dc.identifier.issn16800737
dc.identifier.reponamereponame:Repositorio Institucional Universidad de Medellínspa
dc.identifier.urihttps://hdl.handle.net/11407/4275
dc.language.isoeng
dc.publisherSpringer Verlagspa
dc.publisher.facultyFacultad de Ciencias Básicasspa
dc.relation.ispartofIFMBE Proceedingsspa
dc.relation.ispartofIFMBE Proceedings Volume 60, 2017, Pages 38-41spa
dc.relation.isversionofhttps://www.scopus.com/inward/record.uri?eid=2-s2.0-85018409745&doi=10.1007%2f978-981-10-4086-3_10&partnerID=40&md5=280d9472ab3c08a89e7be6b0469e002e
dc.relation.referencesAliot, E., Haissaguerre, M., & Jackman, W. (2008). Catheter Ablation of Atrial Fibrillationspa
dc.relation.referencesCourtemanche, M., Ramirez, R. J., & Nattel, S. (1998). Ionic mechanisms underlying human atrial action potential properties: Insights from a mathematical model. American Journal of Physiology - Heart and Circulatory Physiology, 275(1 44-1), H301-H321.spa
dc.relation.referencesCourtemanche, M., Ramirez, R. J., & Nattel, S. (1999). Ionic targets for drug therapy and atrial fibrillation-induced electrical remodeling: Insights from a mathematical model. Cardiovascular Research, 42(2), 477-489. doi:10.1016/S0008-6363(99)00034-6spa
dc.relation.referencesFicker, E., Jarolimek, W., Johann, K., Baumann, A., & Brown, A. M. (1998). Molecular determinants of dofetilide block of HERG K+ channels. Circulation Research, 82(3), 386-395.spa
dc.relation.referencesGoralnick, E., & Bontempo, L. J. (2015). Atrial fibrillation. Emergency Medicine Clinics of North America, 33(3), 597-612. doi:10.1016/j.emc.2015.04.008spa
dc.relation.referencesJaiswal, A., & Goldbarg, S. (2014). Dofetilide induced torsade de pointes: Mechanism, risk factors and management strategies. Indian Heart Journal, 66(6), 640-648. doi:10.1016/j.ihj.2013.12.021spa
dc.relation.referencesJanuary, C. T., Wann, L. S., & Alpert, J. S. (2014). AHA/ACC/HRS guideline for the management of patients with atrial fibrillation: Executive summary: A report of the american college of Cardiology/American heart association task force on practice guidelines and the heart rhythm society. J Am Coll Cardiol, 212.spa
dc.relation.referencesJurkiewicz, N. K., & Sanguinetti, M. C. (1993). Rate-dependent prolongation of cardiac action potentials by a methanesulfonanilide class III antiarrhythmic agent: Specific block of rapidly activating delayed rectifier K+ current by dofetilide. Circulation Research, 72(1), 75-83.spa
dc.relation.referencesKneller, J., Zou, R., Vigmond, E. J., Wang, Z., Leon, L. J., & Nattel, S. (2002). Cholinergic atrial fibrillation in a computer model of a two-dimensional sheet of canine atrial cells with realistic ionic properties. Circulation Research, 90(9), E73-87.spa
dc.relation.referencesLauer, M. R. (2001). Dofetilide: Is the treatment worse than the disease? Journal of the American College of Cardiology, 37(4), 1106-1110. doi:10.1016/S0735-1097(01)01146-9spa
dc.relation.referencesOhler, A., Amos, G. J., Wettwer, E., & Ravens, U. (1994). Frequency-dependent effects of E-4031, almokalant, dofetilide and tedisamil on action potential duration: No evidence for "reverse use dependent" block. Naunyn-Schmiedeberg's Archives of Pharmacology, 349(6), 602-610. doi:10.1007/BF01258466spa
dc.relation.referencesSaiz, J., Ferrero Jr., J. M., Monserrat, M., Gomis-Tena, J., Chorro, J., & Ferrero, A. (2003). Effects of the antiarrhythmic drug dofetilide on myocardial electrical activity: A computer modelling study. Paper presented at the Computers in Cardiology, 30 291-294.spa
dc.relation.referencesTande, P. M., Bjørnstad, H., Yang, T., & Refsum, H. (1990). Rate-dependent class III antiarrhythmic action, negative chronotropy, and positive inotropy of a novel IK blocking drug, UK-68,798: Potent in guinea pig but no effect in rat myocardium. Journal of Cardiovascular Pharmacology, 16(3), 401-410.spa
dc.relation.referencesVan Wagoner, D. R. (2003). Electrophysiological remodeling in human atrial fibrillation. PACE - Pacing and Clinical Electrophysiology, 26(7 II), 1572-1575.spa
dc.relation.referencesVoigt, N., Rozmaritsa, N., Trausch, A., Zimniak, T., Christ, T., Wettwer, E., . . . Ravens, U. (2010). Inhibition of IK,ACh current may contribute to clinical efficacy of class i and class III antiarrhythmic drugs in patients with atrial fibrillation. Naunyn-Schmiedeberg's Archives of Pharmacology, 381(3), 251-259. doi:10.1007/s00210-009-0452-6spa
dc.relation.referencesZimetbaum, P. (2012). Antiarrhythmic drug therapy for atrial fibrillation. Circulation, 125(2), 381-389. doi:10.1161/CIRCULATIONAHA.111.019927spa
dc.relation.referencesZipes, D. P., & Jalife, J. (1995). Cardiac Electrophysiology: From Cell to Bedside.spa
dc.rights.accessrightsinfo:eu-repo/semantics/restrictedAccess
dc.sourceScopusspa
dc.subject.proposalAntiarrhythmic drugeng
dc.subject.proposalAtrial fibrillationeng
dc.subject.proposalDofetilideeng
dc.subject.proposalIn silico modeleng
dc.subject.proposalBiomedical engineeringeng
dc.subject.proposalElectric rectifierseng
dc.subject.proposalElectrophysiologyeng
dc.subject.proposalAction potential durationseng
dc.subject.proposalAntiarrhythmic drugeng
dc.subject.proposalAtrial fibrillationeng
dc.subject.proposalCardiac arrhythmiaeng
dc.subject.proposalConcentration-dependenteng
dc.subject.proposalDofetilideeng
dc.subject.proposalIn-silico modelseng
dc.subject.proposalPotassium currentseng
dc.subject.proposalDiseaseseng
dc.titleDofetilide effect on human atrial action potential under normal and atrial fibrillation conditions. In silico studyspa
dc.typeConference Paper
dc.type.driverinfo:eu-repo/semantics/conferenceObject
dc.type.versioninfo:eu-repo/semantics/publishedVersion

Archivos

Colecciones

Indexados Scopus